ArticleNature communications2026

Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer.

Krishnan K Mahadevan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.